Oral GLP-1 Drug Development Trends Enter a Rapid Growth Phase Currently, there are 84 oral small-molecule GLP-1 drug candidates in development worldwide, with 52 already in clinical stages
Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial
There were no significant differences between the change in cognitive performance in the placebo versus exenatide groups (Fig
For histological analysis, rat joint sections from all groups were stained with hematoxylin and eosin, and the pictures of stained joint tissues were captured by LED optical microscope (Leica DM2500)
Individuals with higher metabolic rates have lower levels of reactive oxygen species in vivo